UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

NCT06743503 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Large B-cell Lymphoma

Interventions

GENETIC: UB-VV400
DRUG: Rapamycin

Sponsor

Nanjing IASO Biotechnology Co., Ltd.

Collaborators

[object Object]